PRIMARY OBJECTIVE:~I. To collect preliminary statistical data (mean changes and standard deviations) on two omega-3 supplementation (omega-3 fatty acid) regimens (1.65 g/day and 3.3 g/day) compared to placebo for reducing cancer-related fatigue (CRF) in fatigued breast cancer survivors.~OUTLINE: Patients are randomized to 1 of 3 arms.~ARM I: Patients receive low-dose omega-3 fatty acid supplementation orally (PO) twice daily (BID) and placebo PO BID for 6 weeks.~ARM II: Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.~ARM III: Patients receive placebo PO BID for 6 weeks.
This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.